<DOC>
	<DOCNO>NCT00931411</DOCNO>
	<brief_summary>Atopic dermatitis one frequent skin disease . The disease often bad winter month skin drier . Mild moderate case atopic dermatitis often control moisturizer alone . The use moisturizers show beneficial effect atopic dermatitis . It break dry skin cycle hydrate upper layer skin may prevent recurrence disease reduce use cream ointment medication corticosteroid . Formulation 609580 20 developed keep moisturize efficacy formulation 609209 improve tolerance cosmetic acceptability ( easy apply , nice texture , etc. ) . The new formulation contain quantity shea butter glycerin different excipient ( inactive substance ) commercial product . In addition , vitamin B3 add see could help reduce itch . The purpose study determine safety efficacy two study product child atopic dermatitis . One study product ( formulation 609580 20 ) commercially available ( outside clinical trial one ) . The study product ( formulation 609209 ) approve Canada currently available commercially trade name Lipikar Baume . For study child randomly assign one follow two group : - Group 1 : 50 child receive formulation 609209 , commercial formula 42 day receive formulation 609580 20 , new formula , 14 day . - Group 2 : 50 child receive formulation 609580 20 , new formula , 42 day receive formulation 609209 , commercial formula , 14 day .</brief_summary>
	<brief_title>Tolerance Efficacy Formulation 609580 20 Versus Formulation 609209 Children With Atopic Dermatitis</brief_title>
	<detailed_description>A randomized clinical trial perform five ( 5 ) center ( Montreal , Laval , Quebec City , ( Quebec ) ; Markham , London ( Ontario ) , Canada ) . One hundred ( 100 ) patient enrol study . Subjects parent ( ) guardian ask present clinic five ( 5 ) visit ( Screening , D0 , D7 , D42 , D56 ) . Formulation 609580 20 609209 applied twice day ( morning evening ) whole body total 42 day crossover two formulation . Efficacy evaluate D0 , D7 D42 measure SCORAD ( score atopic dermatitis ) . Tolerance evaluate investigator D7 , D42 D56 . Global efficacy measure parent investigator D7 D42 . Medical photograph ( optional ) lesion take patient consent D0 D42 . A crossover two product occur day 42 cosmetic acceptability compare D42 D56 . Skin examination perform visit . A quality life questionnaire fill parent ( ) D0 D42 .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>312 year age Suffering mild moderate atopic dermatitis amenable treatment moisturizer SCORAD ( score atopic dermatitis ) 1030 screen Day 0 Diagnosis atopic dermatitis must meet Hanifin 's criterion ( least 3 basic feature least 3 minor feature ; please refer appendix D ) Atopic dermatitis , opinion investigator , stable past 28 day Subject parent able apply study product twice day ( morning evening ) 56 day period Subject parent agree change child 's lifestyle study period ( include usual body hygiene product ( soap ) , number baths shower per day , laundry detergent fabric softener use wash child 's clothes ) Subject parent agree child use test product body emollient whole body study period Subject parent available completely follow study child Subject parent able willing sign inform consent form comply study regulation protocol Subject another dermatological condition could interfere clinical evaluation include infected atopic dermatitis lesion Subject previous history allergy cosmetic product ingredient test formulation Subject receive systemic treatment , include PUVA ( psoralen ultraviolet A ) therapy atopic dermatitis within 28 day prior screen Subject receive topical immunomodulators atopic dermatitis ( pimecrolimus tacrolimus ) within 14 day Day 0 Subject receive phototherapy within 14 day Day 0 Subject intend expose him/herself sun trial Subject know allergy component test product Subject use experimental treatment within 14 day Day 0 Subject use topical corticosteroid class IIV within 14 day Day 0</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Atopic Dermatitis</keyword>
	<keyword>Vitamin B3</keyword>
</DOC>